Aminolevulinic acid: Pharmacological profile and clinical indication

Expert Opinion on Investigational Drugs

Volumn 10, Issue 6, 2001, Pages 1139-1156

  Lang, K ^a   Lehmann, P ^a   Bolsen, K ^a   Ruzicka, T ^a   Fritsch, C ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Aminolevulinic acid; Fluorescence diagnosis; Photodynamic therapy; Photosensitiser; Porphyrins; Tumour diagnosis; Tumour therapy

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; PHOTOSENSITIZING AGENT; PORPHYRIN;

ACNE VULGARIS; ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DERMATOLOGY; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; ENDOTHELIUM LESION; EPITHELIUM TUMOR; ERYTHEMA; EXPERIENCE; FEMALE; FLUORESCENCE; GASTROENTEROLOGY; GYNECOLOGY; HUMAN; HUMAN TISSUE; LASER; MALE; MULTICENTER STUDY; NEPHROLOGY; NEUROLOGY; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PSORIASIS; PULMONOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYNDROME DELINEATION; TREATMENT INDICATION; UROLOGY; VIRUS INFECTION;

AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; CLINICAL TRIALS; DRUG EVALUATION; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 0034992299     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.6.1139     Document Type: Article

References (105)

1. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
2. Neoplasms of the lung
3. Treatment of oesophageogastric tumors
4. Management of superficial bladder cancer: What is new?
5. Laparoscopic radical and partial nephrectomy
6. Biology and treatment of malignant glioma
7. Endometriosis: An overview of the disease and its treatment
8. Margin status and excision of cervical intraepithelial neoplasia: A review
9. Single episode photodynamic therapy and vulval intraepithelial neoplasia Type III resistant to conventional therapy
10. Breast cancer: Detection and management
11. A comparison of the phototoxicity of protoporphyrin, coproporphyrin and uroporphyrin using a cellular system in vitro
12. Photodynamic therapy in oncology: Mechanism and clinical use
13. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-κB DNA binding
14. Photodynamic therapy mediated induction of early response genes
15. Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy
16. Effects of photodynamic therapy on leucocyte-endothelium interaction: Differences between normal and tumour tissue
17. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience
18. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs
19. 5-Aminolevulinic acid-induced protoporphyrin IX accumulation in tissues: Pharmacokinetics after oral or intravenous administration
20. Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid
21. Hemodynamic effects of 5-aminolevulinic acid in humans
22. 5-Aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters
23. Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine
24. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolevulinic acid
25. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma
26. A dose-finding study of photodynamic therapy (PDT) with Metvix® in actinic keratoses (AK)
27. A dose-finding study of photodynamic therapy (PDT) with Metvix® in patients with basal cell carcinoma (BCC)
28. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas and basal cell carcinomas?
29. Photodynamic therapy of epithelial skin tumours using δ-aminolaevulinic acid and desferrioxamine
30. Repetitive photodynamic therapy with topical d-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours
31. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study
32. Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses
33. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester
34. Photodynamic therapy in dermatology
35. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary skin cancer
36. Treatment of superficial basal cell carcinomas using topically applied δ-aminolevulinic acid and a filtered xenon lamp
37. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease
38. Photodynamic therapy: A better treatment for widespread Bowen's disease
39. Photodynamic therapy for multiple skin cancers
40. Photodynamic therapy in the treatment of malignant tumours of the skin and head and neck
41. Photodynamic therapy of superficial malignancies with Npe6 in man
42. Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid and exposure to red light and infrared light
43. Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5-aminolevulinic acid
44. Photodiagnostic test methods III. Fluorescence diagnosis with aminolevulinic acid induced porphyrins
45. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid
46. Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light
47. Successful surgery of multiple recurrent basal cell carcinomas guided by photodynamic diagnosis
48. Photodynamic diagnosis and therapy in dermatology
49. Photodynamic therapy in dermatology: Recent developments
50. Photodynamic therapy on a patient with xeroderma pigmentosum
51. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid
52. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid
53. Photodynamic therapy for inoperable vulval Paget's disease using δ-aminolevulinic acid: Successful management of a large skin lesion
54. Carbon dioxide laser treatment of extrammamary Paget's disease guided by photodynamic diagnosis
55. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis
56. The treatment of erythroplasia of Queyrat by topical aminolevulinic acid photodynamic therapy
57. Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow-up 5-aminolevulinic acid induced protoporphyrin IX fluorescence
58. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid
59. Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic acid-induced protoporphyrin IX fluorescence
60. Visualizing carcinomas of the mouth cavity by stimulating synthesis of fluorescent protoporphyrin IX
61. Systemic photodynamic therapy is a safe and effective treatment for psoriasis
62. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolevulinic acid photodynamic therapy
63. Treatment of psoriasis by topical photodynamic therapy with polychromatic light
64. Therapy of acne with visible light. Decreased irradiation time by using a blue-light high-energy lamp
65. Topical ALA-photodynamic therapy for the treatment of acne vulgaris
66. Topical photodynamic therapy for localized scleroderma
67. Treatment of viral infections with 5-aminolevulinic acid and light
68. Photodynamic therapy with 5-aminolevulinic acid or placebo for recalcitrant foot and hand warts: Randomised double-blind trial
69. Topical photodynamic therapy in verrucae. A pilot study
70. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid
71. Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid
72. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolevulinic acid: Implications for photodynamic treatment
73. PDT of hirsutism
74. Fluorescence diagnosis of endometriosis using 5-aminolevulinic acid
75. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence
76. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid
77. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid
78. Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid
79. 5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: A pharmacokinetic study
80. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization
81. Endoscopic photodynamic diagnosis: Oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions
82. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid
83. Photodynamic therapy of cancer of the esophagus using systemic aminolevulinic acid and a non laser light source: A Phase I/II study
84. Photodynamic therapy using 5-aminolevulinic aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasia
85. Fluorescence detection of bladder tumors with 5-amino-levulinic acid
86. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy
87. Kidney-preserving tumour resection in renal cell carcinoma with photodynamic detection by 5-aminolevulinic acid: Preclinical and preliminary clinical results
88. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence
89. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients
90. Topical aminolevulinic acid HCL photodynamic therapy
91. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses
92. A pivotal study of photodynamic therapy with Metvix cream 160 mg/g in patients with basal cell carcinoma unsuitable to conventional therapy
93. A prospective, randomized study comparing photodynamic therapy (PDT) with Metvix®, to cryotherapy in actinic keratoses (AK)
94. Fluoresenzgestützte Resektion maligner Gliome. Phase-3-Studie mit 5-aminolävulinsäure
95. Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism
96. Allergic contact dermatitis from delta-aminolevulinic acid used for photodynamic therapy
97. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses
98. Treatment of a large superficial basal cell carcinoma of the breast. Combination of photodynamic therapy and surgery controlled by photodynamic diagnosis
99. Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application
100. Photosensitisation and photodynamic therapy of oesophageal, duodenal and colorectal tumours using 5 aminolevulinic acid induced protoporphyrin IX-a pilot study
101. Expression kinetics of the (proto) oncogenes c-myc and bcl-2 following photodynamic treatment of normal and transformed human fibroblasts with 5-aminolevulinic acid-stimulated endogenous protoporphyrin IX
102. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): Current clinical and development status
103. High efficiency of 5-aminolevulinate-photodynamic treatment using UVA-irradiation
104. Kobner reaction induced by photodynamic therapy using δ-aminolevulinic acid. A case report